Information  X 
Enter a valid email address

EPIC/TIDM matching '0EE0'

Date
Time Source
Company
Announcement
06 Jul 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
21 Jun 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
31 May 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
22 May 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
10 May 2019 1:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
07 May 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
02 May 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
01 May 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
29 Apr 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress
15 Apr 2019 5:15 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
08 Apr 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
29 Mar 2019 11:00 am GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
01 Mar 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
28 Feb 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
27 Feb 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
15 Feb 2019 12:24 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
08 Feb 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
04 Feb 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
30 Jan 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
22 Jan 2019 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
03 Dec 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
19 Nov 2018 5:15 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
15 Nov 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
06 Nov 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
05 Nov 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Host Research & Development Day on Monday, November 19 in New York City
31 Oct 2018 11:00 am GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
18 Oct 2018 11:55 am GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
17 Oct 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
16 Oct 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
28 Sep 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
24 Sep 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
30 Aug 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure to Participate at Multiple Upcoming Conferences
23 Aug 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
08 Aug 2018 12:00 pm GNW   Factsheet uniQure Inc. (0EE0) uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
28 Jun 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
13 Jun 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces New Appointments to its Board of Directors
29 May 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
21 May 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
18 May 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
07 May 2018 4:53 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
03 May 2018 12:38 am GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Pricing of its Public Offering
01 May 2018 9:10 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Proposed Public Offering
30 Apr 2018 5:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
  12:05 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
14 Mar 2018 11:00 am GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces 2017 Financial Results and Recent Company Progress
27 Feb 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure to Participate in Multiple Conferences in March
01 Feb 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure to Participate in Multiple Conferences in February
22 Jan 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease
08 Jan 2018 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value
18 Dec 2017 12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
11 Dec 2017 9:01 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Added to NASDAQ Biotechnology Index
  12:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
09 Dec 2017 2:00 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting
01 Nov 2017 1:10 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
  11:00 am GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress
31 Oct 2017 8:09 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Multiple Company Presentations at Upcoming November Conferences
27 Oct 2017 9:03 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Closing of its Public Offering
25 Oct 2017 1:14 am GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Pricing of its Public Offering
23 Oct 2017 9:09 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Announces Proposed Public Offering
19 Oct 2017 12:05 pm GNW   Factsheet uniQure N.V. (0EE0) uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t